Clinical profile of patients considered for biphasic insulin aspart 30:: baseline characteristics of insulin naive patients from the IMPROVE™ Study

被引：0
|
作者：
Kawamori, Ryuzo [1 ]
Valensi, Paul [2 ]
Orskov, Cathrine [3 ]
Ligthelm, Robert J. [4 ]
机构：
[1] Juntendo Univ, Sch Med, Tokyo 113, Japan
[2] Univ Paris 13, Jean Verdier Hosp, Dept Endocrinol Diabetol Nutr, Bondy, France
[3] Novo Nordisk AS, Copenhagen, Denmark
[4] EHM Clin, Rotterdam, Netherlands
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2008年 / 79卷
关键词：
D O I：
10.1016/S0168-8227(08)70804-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S65 / S66
页数：2
相关论文
共 50 条
  • [1] Clinical profile of patients starting on biphasic insulin aspart 30:: baseline characteristics from China, Japan, Poland and Italy from the IMPROVE™ study
    Yang Wenying
    Kawamori, Ryuzo
    Hansen, Jes B.
    Ligthelm, Robert
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S66 - S66
  • [2] Clinical profile of patients considered for BIAsp 30:: Baseline characteristics from China, Japan and Poland from the IMPROVE™ study
    Wenying, Yang
    Kawamori, Ryuzo
    Valensi, Paul
    Gylvin, Titus
    Ligthelm, Robert
    [J]. DIABETES, 2007, 56 : A627 - A627
  • [3] Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naive Patients with Type 2 Diabetes
    Esteghamati, Alireza
    Nakhjavani, Manouchehr
    Aminorroaya, Ashraf
    Aboutorabi, Robabeh
    Niafar, Mitra
    Mohammadi, Mohammad
    Parvaresh, Ehsan
    [J]. JOURNAL OF DIABETES & METABOLISM, 2011, 2 (03)
  • [4] Baseline characteristics of the Indian cohort from the IMPROVE™ study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes
    Shah, Siddharth
    Das, A. K.
    Kumar, Ajay
    Unnikrishnan, A. G.
    Kalra, Sanjay
    Baruah, M. P.
    Ganapathi, B.
    Sahay, R. K.
    [J]. ADVANCES IN THERAPY, 2009, 26 (03) : 325 - 335
  • [5] Baseline characteristics of the Indian cohort from the IMPROVE™ study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes
    Siddharth Shah
    A. K. Das
    Ajay Kumar
    A. G. Unnikrishnan
    Sanjay Kalra
    M. P. Baruah
    B. Ganapathi
    R. K. Sahay
    [J]. Advances in Therapy, 2009, 26 : 325 - 335
  • [6] Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study
    Yang, Wenying
    Gao, Yan
    Liu, Guoliang
    Chen, Lulu
    Fu, Zuzhi
    Zou, Dajin
    Feng, Ping
    Zhao, Zhigang
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) : 101 - 107
  • [7] LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS
    Ligthelm, R.
    Christensen, T. E.
    Thomsen, T. L.
    Yang, W.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A402 - A402
  • [8] Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects
    Hassan, Mohammad Imtiaz
    Aamir, Azizul Hasan
    Miyan, Zahid
    Siddiqui, Laiq Ahmed
    Mahmood, Shahid
    Vohra, Ejaz Ahmed
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2013, 63 (10) : 1290 - 1294
  • [9] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
    Kawamori, Ryuzo
    Valensi, Paul
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
  • [10] Improved Safety and Efficacy Profile in Patients with Type 2 Diabetes Treated with Biphasic Insulin Aspart 30 (BIAsp 30): Iran Subgroup of the IMPROVE Study
    Esteghamati, Alireza
    Rajabian, Reza
    Amini, Masoud
    Bahrami, Amir
    Khamseh, Mohammad Ebrahim
    Ardekani, Mohammad Afkhami
    Rizi, Ehsan Parvaresh
    [J]. DIABETES, 2009, 58 : A527 - A527
12345